NovaGo Therapeutics clôture un tour de financement de série B de 30 millions de dollars américains pour faire avancer son étude de validation de principe sur les lésions médullaires aiguës

Summary

NovaGo Therapeutics closed a $30 million Series B funding round led by Neurimmune and Pureos to advance a proof-of-concept study for acute spinal cord injury treatment. The round was supported by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.